Invivyd Bets on Next-Gen Antibodies, Raises $125M Amid Evolving COVID Landscape

NEW YORK, NY – November 17, 2025 –

Funding Commercialization and Pipeline Expansion

Invivyd, Inc. successfully completed a $125 million public offering of common stock, the company announced this week. The biopharmaceutical firm intends to utilize the net proceeds to prepare for the potential commercial launch of VYD2311, a next-generation monoclonal antibody targeting COVID-19, while simultaneously advancing its research and development pipeline targeting respiratory syncytial virus (RSV) and measles. The move signals a strategic shift for the company, which received Emergency Use Authorization earlier this year for its antibody, pemivibart, focused on pre-exposure prophylaxis against COVID-19 in immunocompromised individuals.

The offering, priced at $2.50 per share, drew mixed reactions from investors, with the stock experiencing a slight dip in after-hours trading following the announcement. “There's a cautious optimism surrounding Invivyd,” one analyst commented anonymously. “While VYD2311 shows promise, the market is heavily saturated with COVID-19 treatments, and the success of any new entry hinges on demonstrable efficacy against current variants.” Cantor Fitzgerald & Co. served as the sole book-running manager for the offering, with H.C. Wainwright & Co. acting as the lead manager.

VYD2311: A Potential “Vaccine Alternative”

VYD2311 is designed to provide durable protection against symptomatic COVID-19, potentially offering a “vaccine alternative” for individuals who may not respond effectively to traditional vaccines. Preclinical and early clinical data released by Invivyd indicate a favorable safety profile and a remarkably long half-life of up to 76 days. This could lead to less frequent dosing and improved patient compliance.

The company is aligning with the FDA on a rapid pathway for Biologics License Application (BLA) approval for VYD2311, hoping to secure approval for a broad population of Americans, including those who are immunocompromised. The anticipated launch of Phase 3 trials, known as DECLARATION and LIBERTY, will be critical in demonstrating the antibody’s efficacy and safety in a larger patient population. “The long half-life is certainly an attractive feature,” noted another industry observer. “It could differentiate VYD2311 from other mAbs that require more frequent infusions.”

Financial Health and Funding Needs

Despite the successful funding round, Invivyd’s financial future remains uncertain. Recent quarterly reports reveal the company continues to operate at a loss, and management has explicitly stated “substantial doubt” about its ability to continue as a going concern without securing additional funding. While revenue increased significantly in the third quarter of 2025, driven by sales of pemivibart, operating expenses remain high. “They’ve made significant strides in improving their revenue stream,” explained one financial analyst. “However, they need to demonstrate a clear path to profitability to reassure investors.”

The $125 million raised through the public offering is intended to bolster Invivyd’s liquidity and fund its ongoing research and development efforts, but analysts are questioning whether it will be enough. The company is facing increasing competition in the crowded infectious disease market, and the cost of bringing new treatments to market is substantial. “They’ve made a bold bet on VYD2311 and their broader pipeline,” said one investor. “Now, they need to deliver on that promise.”

Expanding Beyond COVID-19

Invivyd’s strategic vision extends beyond COVID-19. The company is actively pursuing the development of treatments for RSV and measles, recognizing the significant unmet medical needs in these areas. The emergence of new RSV vaccines from companies like GSK and Pfizer has intensified competition in this space, but Invivyd believes its monoclonal antibody approach could offer a more durable and effective solution for vulnerable populations.

While measles is largely preventable through vaccination, outbreaks continue to occur, particularly in communities with low vaccination rates. Invivyd’s research into potential measles treatments could address this ongoing public health challenge, providing an additional layer of protection for those at risk. “Diversifying their pipeline is a smart move,” commented a healthcare analyst. “It reduces their reliance on a single product and positions them for long-term growth.” The company's ability to navigate the complex regulatory landscape and secure funding for these initiatives will be critical to its success.